Immuron Limited (IMRN) News
Filter IMRN News Items
IMRN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
IMRN News Highlights
- For IMRN, its 30 day story count is now at 2.
- Over the past 18 days, the trend for IMRN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about IMRN are DRUG, ASX and BASE.
Latest IMRN News From Around the Web
Below are the latest news stories about IMMURON LTD that investors may wish to consider to help them evaluate IMRN as an investment opportunity.
Immuron Clinical Trials UpdateHighlights: US Naval Medical Research Command (NMRC) campylobacter clinical program completes in-patient phase Manufacture of IMM-529 drug substance to support the Pre-IND information package has been completedPre-IND submission to the U.S. Food and Drug administration (FDA) planned for H1 2024 Travelan® clinical study inpatient phase completed and 6 month follow up visits planned MELBOURNE, Australia, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian base |
Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical StudyHighlights: First participants enrolled in the US Naval Medical Research Command Clinical Trial Clinical Study initiated to evaluate the efficacy of a new Immuron clinical product to protecting volunteers against moderate to severe campylobacteriosisNew CampETEC product is a prophylactic therapeutic designed to protect against Campylobacter and Enterotoxigenic Escherichia coli (ETEC) infections, two of the major causes of Travelers’ diarrhea The in-patient stage of the study is anticipated to be |
Immuron CEO, Steven Lydeamore Investor Webinar PresentationMELBOURNE, Australia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite shareholders to attend an investor webinar “Coffee Microcaps Morning Meeting”, to be held on Thursday, 30th of November, 2023, 9:00am ADEST. CEO Steven Lydeamore will provide an overview and update on the business and upcoming milestones. Following the presentation, attendees will have the opportunity to ask q |
Immuron Announces Travelan® Clinical Study Cohort 2 commencesHighlights: Second cohort of 34 healthy volunteers enrolled in the Travelan® Clinical Trial Clinical Trial to examine a dosing regimen for Travelan® more suited to the US military has commenced the second cohortThe clinical study 6 month follow up of Cohorts 1 and 2 anticipated to be completed in April 2024Travelan® is known to protect against the onset of Traveler’s diarrhea (TD), the most common illness reported by travelers MELBOURNE, Australia, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Immuron Limit |
Immuron achieves record quarterly Travelan® salesHighlights: Record quarterly Travelan® sales of $1,550,240Total sales of A$1,565,767 in Q1, FY24 $1,508,933 increase on Q1, FY23 sales130% higher than pre-pandemic period Q1, FY20 sales MELBOURNE, Australia, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record quarterly sales (unaudited net sales) of its over-the-counter gastrointestinal and digestive health immune supplemen |
Immuron Limited Announces Participation in the LD Micro Main Event XVIPresentation on Wednesday, October 4th at 11:00 PT Melbourne, Australia--(Newsfile Corp. - September 18, 2023) - Immuron Limited (NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, announced today that it will be presenting at the 16th annual Main Event on Wednesday, October 4th at 11:00 PT at the Luxe Sunset Boulevard Hotel. Steven Lydeamore, CEO, will be giving the presentation. "We know what this event means to our industry and ... |
Immuron hails record monthly sales of TravelanImmuron Ltd (NASDAQ:IMRN, ASX:IMC) CEO Steve Lydeamore speaks with Proactive following news the company has achieved record monthly sales of its over-the-counter gastrointestinal supplement Travela... |
Immuron achieves record monthly Travelan® salesHighlights: Record monthly Travelan® salesAustralian sales of A$1.18 M in August 2023 (7984% increase on August 2022 sales) MELBOURNE, Australia, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record monthly sales (unaudited net sales) of its over-the-counter gastrointestinal and digestive health immune supplement Travelan®. Immuron previously reported (August 9, 2023) that |
Immuron CEO, Steven Lydeamore to present at H.C. WainwrightMELBOURNE, Australia, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting virtually at the H.C. Wainwright 25th Annual Global Investment Conference on September 11th. The webcast to this presentation will be available here at 7am Eastern Daylight Time / 9pm Australian Eastern Standard time on September 11th. A copy of |
Planet MicroCap Review Magazine for Summer 2023 Now OnlinePlanet MicroCap, a global multimedia financial news and publishing company that focuses on delivering news, information, data and analytics for publicly traded microcap companies, today announced that the Summer 2023 Issue of the Planet MicroCap Review Magazine is now available in digital format. |